Stockscreener 앱 받기
2.115
4.44%
0.09
전일 마감가:
$2.025
열려 있는:
$2.02
하루 거래량:
200.85K
Relative Volume:
0.54
시가총액:
$75.60M
수익:
-
순이익/손실:
$-42.94M
주가수익비율:
-1.3056
EPS:
-1.62
순현금흐름:
$-33.64M
1주 성능:
-6.00%
1개월 성능:
-32.21%
6개월 성능:
-40.59%
1년 성능:
-66.27%
1일 변동 폭
$2.015
$2.14
1주일 범위
$1.90
$2.23
52주 변동 폭
$1.53
$6.68
Pds Biotechnology Corporation Stock (PDSB) Company Profile
명칭
Pds Biotechnology Corporation
전화
800-208-3343
주소
303A COLLEGE ROAD EAST, PRINCETON
PDSB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| PDSB | 2.115 | 75.60M | 0 | -42.94M | -33.64M | -1.62 |
| VRTX | 449.81 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 748.23 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 588.46 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 247.98 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 106.53 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Pds Biotechnology Corporation Stock (PDSB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-11-01 | 개시 | B. Riley Securities | Buy |
| 2021-06-28 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-11-10 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-05-27 | 개시 | Alliance Global Partners | Buy |
| 2020-03-09 | 개시 | Noble Capital Markets | Outperform |
| 2019-10-24 | 개시 | Chardan Capital Markets | Buy |
모두보기
Pds Biotechnology Corporation 주식(PDSB)의 최신 뉴스
Down -35.74% in 4 Weeks, Here's Why PDS Biotechnology (PDSB) Looks Ripe for a Turnaround - Yahoo Finance
PDS Biotechnology’s (PDSB) Buy Rating Reiterated at HC Wainwright - Defense World
PDS Biotechnology's (PDSB) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
PDS Biotechnology to Present at H.C. Wainwright Bioconnect Virtual Conference - StockTitan
PDS Biotechnology Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
PDS Biotechnology Corporation (NASDAQ:PDSB) Q3 2024 Earnings Call Transcript - Insider Monkey
PDS Biotechnology Corporation (PDSB) Quarterly 10-Q Report - Quartz
PDS Biotechnology: Q3 Earnings Snapshot - New Haven Register
PDS Biotechnology Corp (PDSB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ... - Yahoo Finance
PDS Biotechnology Corp (PDSB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ... By GuruFocus - Investing.com Canada
PDS Biotechnology Highlights Clinical Progress and Q3 Results - TipRanks
Earnings call: PDS Biotech reports progress in HPV cancer trials By Investing.com - Investing.com Canada
PDSB stock touches 52-week low at $2.21 amid market challenges - Investing.com India
PDS Biotechnology Shares Down 18% After Phase 3 Trial Modifications - MarketWatch
PDS Biotechnology Corporation Provides Clinical Programs Update - Marketscreener.com
U.S. Stock market: Nuvectis Pharma saw a sharp decline of 53.89% while AgEagle Aerial Systems surged by 133.74% in early trading - Business Upturn
PDS Biotech Provides Clinical Programs Update and Reports Third Quarter 2024 Financial Results - The Manila Times
PDS Biotech Reports $10.7M Q3 Loss, Streamlines Phase 3 Trial Design | PDSB Stock News - StockTitan
PDS Biotechnology (PDSB) to Release Earnings on Thursday - Defense World
PDS Biotechnology (NASDAQ:PDSB) Downgraded to "Sell" Rating by StockNews.com - MarketBeat
PDS Biotechnology (PDSB) Set to Announce Quarterly Earnings on Thursday - MarketBeat
PDS Biotech: Interview With President And CEO Frank Bedu-Addo About The Immunotherapy Company - Pulse 2.0
PDS Biotechnology Sets Q3 Earnings Call: Clinical Updates Expected Nov 14 | PDSB Stock News - StockTitan
Contrasting Semiconductor Manufacturing International (OTCMKTS:SMICY) & POET Technologies (NASDAQ:POET) - Defense World
StockNews.com Initiates Coverage on Ark Restaurants (NASDAQ:ARKR) - Defense World
Jones Soda Announces Departure of President and CEO, David Knight, and Appointment of Interim CEO, Paul Norman - Defense World
Mastech Digital (NYSE:MHH) Coverage Initiated by Analysts at StockNews.com - Defense World
PDS Biotechnology Co. (NASDAQ:PDSB) Receives $14.25 Consensus Price Target from Analysts - MarketBeat
Head-To-Head Analysis: Edison International (NYSE:EIX) and AltC Acquisition (NYSE:ALCC) - Defense World
FS KKR Capital Corp. (NYSE:FSK) Given Consensus Rating of “Hold” by Brokerages - Defense World
StockNews.com Begins Coverage on TRX Gold (NYSE:TRX) - Defense World
Mastech Digital (NYSE:MHH) Now Covered by Analysts at StockNews.com - Defense World
Bowhead Specialty (NYSE:BOW) versus Horace Mann Educators (NYSE:HMN) Critical Survey - Defense World
Zacks Research Issues Negative Estimate for CSX Earnings - Defense World
Hillman Solutions (HLMN) to Announce Quarterly Earnings on Tuesday - Defense World
Evolv Technology Holdings CEO terminated, replaced by Michael Ellenbogen as Interim CEO - Defense World
Chase (NYSE:CCF) Now Covered by Analysts at StockNews.com - Defense World
PDS Biotechnology (NASDAQ:PDSB) Stock Rating Upgraded by StockNews.com - MarketBeat
HC Wainwright Reaffirms Buy Rating for PDS Biotechnology (NASDAQ:PDSB) - MarketBeat
Is There More Room To Run For This Immunotherapy Company Stock After Hitting New High? - RTTNews
PDS Biotechnology (PDSB) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance
PDS Biotech Announces Presentation of Rationale and Design of First Recurrent Prostate Cancer Trial to Combine an Androgen Receptor Pathway Inhibitor with an Immunocytokine - The Manila Times
Critical Review: PDS Biotechnology (NASDAQ:PDSB) & InflaRx (NASDAQ:IFRX) - Defense World
NY Biopharma Shares Promising Clinical Data - Streetwise Reports
Data Readouts At ASCO (MRUS, ORIC, CGEN, PDSB...) - RTTNews
H.C. Wainwright & Co. Shares Buy Rating on Biotech Co. - Streetwise Reports
PDS Biotechnology Co. (NASDAQ:PDSB) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Europe Aneurysmal Subarachnoid Hemorrhage Drugs Market Size, Spotlight on Future Potentials (2024-2034) - IndiaPolitics.com
CD47 Inhibitors Market Projected to Grow Significantly with Emerging Cancer Therapies by 2034 | DelveInsight - The Malaysian Reserve
Mass. Biotech Receives FDA Approval - Streetwise Reports
PDS Biotechnology Corporation: Buy, Hold, or Sell? Analysts Weigh In Amid Market Challenges - The InvestChronicle
Pds Biotechnology Corporation (PDSB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.80%
0.42%
자본화:
|
볼륨(24시간):